UVA LVG Seed Fund Portfolio

Ceres Nanosciences

Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on the development of research and diagnostic products using its unique and proprietary Nanotrap® particle technology. The Nanotrap® particle technology provides powerful biomarker capture and biofluid sample processing capabilities for a wide array of diagnostic applications and sample handling needs. The Nanotrap® particle technology was invented at George Mason University and developed under funding from the National Institutes of Health (NIH). With support from the NIH, the Defense Advanced Research Projects Agency (DARPA), the Bill and Melinda Gates Foundation, and the Commonwealth of Virginia, Ceres is focused on incorporating this technology into a range of innovative diagnostic products. Learn more at www.ceresnano.com

Year Founded: 2008

UVA LVG Seed Fund Investment: 2018


January 2018 - Ceres Nanosciences reaches product development milestone for point-of-care Lyme disease test and closes on an additional $5.5M of Series A funding

February 2017 - A technology backed by Bill Gates may revolutionize diagnostics for Lyme disease

510Kardiac Devices, Inc.

510 Kardiac is an early stage medical device company developing novel technologies for cardiovascular surgical procedures. The company was co-founded by Dr. Scott Lim, an interventional cardiologist and the Director of the Advanced Cardiac Valve Center at the University of Virginia Health System and the company’s current CEO, Jaime Sarabia, a mechanical engineer with more than 18 years of experience in medical device ventures.

UVA LVG Seed Fund Investment: 2018

Year Founded: 2015


June 2018 - Cardiologist's surgical device backed by UVA investment

May 2018 - Heart Surgery Can be Safer, Thanks to UVA Cardiologist's New Device

Mission Secure

Mission Secure creates cybersecurity solutions that not only make systems more complex and costly to attack, but also take corrective action against cyber-attacks in software. 

UVA LVG Seed Fund Investment: July 2017

Year Founded: 2014



August 2017 - Mission Secure Completes Fourth Successful Financing

July 2017 - Patent Awarded for MSi Platform


Discovered by UVA Professor of Cell Biology and Ophthalmology Dr. Gordon Laurie, TearSolutions' first-in-class therapy is a synthetic form of the protein lacritin which targets the root causes of dry-eye disease. 

UVA LVG Seed Fund Investment: January 2017

Year Founded: 2013



December 2017 - Charlottesville startup gets $8.5 million via Tech/Carilion venture group, Russian company

August 2017 - Dry Eye Deserves Attention

March 2017 - Novel topical peptide for dry eye tackles underlying cause of disease

January 2017 - New Dry Eye Drug is First That Aims to Treat Cause, Rather than Symptoms

January 2017 - Un-dry those eyes: New solutions to treat dry eye disease are progressing successfully

December 2015 - Tears of Joy: UVA Start-up Seeks to Bring New Eye Therapy to Millions

TypeZero Technologies, Inc.

Digital health and personalized medicine company dedicated to revolutionizing the treatment and management of type 1 and type 2 diabetes.

UVA LVG Seed Fund Investment: May 2016

Year Founded: 2015



Unafraid to Ask More: Diabetes